The transaction involves the sale of Mayne Pharma’s contract development and manufacturing operations, together with its Australian and international commercial operations centred on its manufacturing and development facility in Salisbury, South Australia.
The divestment forms part of Mayne Pharma’s broader strategic repositioning and will complete its transition to a specialty pharmaceutical company focused exclusively on the United States.
The MinterEllison team was led by M&A / Capital Markets Partners Sudharshan Senathirajah and Daniel Bell, with support from Senior Associates Oliver Deane and Morgan Lincoln, Associate Mason Bierlein and Lawyer Nat Dermenzies.
Sudharshan Senathirajah said:
We are very pleased to have supported Mayne Pharma on another important transaction as it continues to reposition its business around its US specialty pharmaceutical operations. The sale involved a number of continuing commercial and operational arrangements between the parties post completion.
Daniel Bell added:
We have a longstanding relationship with Mayne Pharma and are proud to have worked alongside the Mayne Pharma team on this significant step in its strategic transformation.
Specialist advice was provided by teams across competition, tax and IP/IT, including Partner Geoff Carter, Senior Associates Tom Faulls and Annabel Green, and Lawyer Michael Sparks on competition matters; Partner Elissa Romanin and Senior Associate Lian Park on tax; and Special Counsel Nicole Reid on IP/IT.
The transaction is subject to ACCC approval and is expected to complete in early 2027.
